• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Vasomune Therapeutics Inc

Monday, June 03, 2024
Company Presentation
Respiratory
Company Presentation Theater 3
Vasomune Therapeutics is a private biotechnology company dedicated to developing the next generation of medical treatments for disease arising from vascular endothelial pathology. Our groundbreaking strategy tackles vascular dysfunction by activating the Tie2 pathway, a critical endothelial specific receptor involved in the maintenance of vascular health. Unlike traditional methods, our innovative, threat-agnostic approach aims to universally combat diseases by minimizing vascular leakage and normalizing endothelial cell activation. This technique has the potential to transform the treatment of a diverse array of illnesses, including pneumonia, acute respiratory distress syndrome, sepsis, hemorrhagic shock, stroke, and vascular dementia, by substantially lowering morbidity and mortality rates and enhancing patient quality of life. Discover how we're leading the charge as a threat-agnostic therapeutic against vascular dysfunction at www.vasomune.com
Vasomune Therapeutics Inc
Company Website: https://vasomune.com/
Lead Product in Development: AV-001 (previously referred to as "vasculotide")
Number Of Unlicensed Products (For Which You Are Seeking Partners): 1

Company HQ City

Toronto

Company HQ State

Ontario

Company HQ Country

Canada

CEO/Top Company Official

Brian E. Jahns, PharmD

Development Phase of Primary Product

Phase II
Primary Speaker
BRIAN JAHNS, PharmD
President & Chief Operating Officer
Vasomune Therapeutics inc
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS